http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
S-228 : Early Intervention in Octogenarians with Non-ST-Elevation Myocardial Infarction
( Zhe Hao Piao ),( Myung Ho Jeong ),( Jae Yeong Cho ),( Hae Chang Jeong ),( Keun-ho Park ),( Doo Sun Sim ),( Nam Sik Yoon ),( Hyun Ju Yoon ),( Young Joon Hong ),( Kye Hun Kim ),( Ju Han Kim ),( Youngk 대한내과학회 2013 대한내과학회 추계학술대회 Vol.2013 No.1
Background and Objectives: Octogenarians with coronary artery disease constitute a high risk group. Most studies documented that octogenarians with non-ST-elevation myocardial infarction (NSTEMI) may derive a greater benefit from an invasive strategy than younger patients, but the optimal timing of such intervention is not well established. We hypothesized that octogenarians with NSTEMI who underwent earlier intervention in the invasive arm would have improved outcomes. Methods: We retrospectively analyzed 567 octogenarians who underwent percutaneous coronary intervention (PCI) and who were enrolled in the Korean Acute Myocardial Infarction Registry. They were divided into 2 groups, an early intervention (PCI done within 24 hours after onset of symptoms; n=228) and deferred intervention (24 to 72 hours; n=339). The primary outcome was the incidence of in hospital death and major bleeding. Secondary clinical endpoints were the 12-month all-cause death and 12-month major adverse cardiac events (MACE), where MACE included all-cause death, recurrent myocardial infarction, target lesion revascularization (TLR), and coronary artery bypass grafting (CABG). Results: There were no significant differences in the incidence of in hospital death (6.4 vs. 5.9%: p=0.808) and major bleeding (0.0 vs. 3.0%: p=0.110) between groups. The secondary clinical endpoints were similar between two groups during 12-month follow-up: all-cause death (8.0 vs. 11.5%: p=0.936), MACE (11.3 vs. 16.9%: p=0.897), recurrent myocardial infarction (0.9 vs. 0.5%: p=0.484), TLR (1.8 vs. 1.6%: p=0.693) and CABG (0.0 vs. 0.5%: p=0.678). Conclusions: In octogenarians with NSTEMI, an early intervention approach does not offer an advantage over a deferred intervention.
Prognostic Value of T Cell Immunoglobulin Mucin-3 in Prostate Cancer
Piao, Yong-Rui,Piao, Long-Zhen,Zhu, Lian-Hua,Jin, Zhe-Hu,Dong, Xiu-Zhe Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.6
Background: Optimal treatment for prostate cancer remains a challenge worldwide. Recently, T cell immunoglobulin mucin-3 (TIM-3) has been implicated in tumor biology but its contribution prostate cancer remains unclear. The aim of this study was to investigate the role of TIM-3 as a prognostic marker in patients with prostate cancer. Methods: TIM-3 protein expression was determined by immunohistochemistry and Western blotting in 137 prostate cancer tumor samples and paired adjacent benign tissue. We also performed cell proliferation assays using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl- 2H tetrazolium bromide (MTT) and cell invasion assays. The effects of small interfering RNA (siRNA)-mediated knockdown of TIM-3 (TIM-3 siRNA) in two human prostate cancer cell lines were also evaluated. Results: TIM-3 expression was higher in prostate cancer tissue than in the adjacent benign tissue (P<0.001). High TIM-3 expression was an independent predictor of both recurrence-free survival and progression-free survival. TIM-3 protein was expressed in both prostate cancer cell lines and knockdown suppressed their proliferation and invasion capacity. Conclusions: TIM-3 expression is associated with a poor prognosis in prostate cancer. Taken together, our resutlts indicate that TIM-3 is a potential prognostic marker in prostate cancer.
Zhe Hao Piao,정명호,정해창,박근호,심두선,홍영준,김주한,안영근 대한심장학회 2015 Korean Circulation Journal Vol.45 No.3
Coronary artery fistula (CAF) with giant aneurysm and accompanied by coronary artery stenosis is a very rare disease. Herein, we report a case of a 76-year-old woman having a complex coronary-to-pulmonary artery fistula associated with a giant aneurysm and accompanied by coronary artery stenosis. The patient was successfully treated using transcatheter coil embolization and coronary stent implantation. Eight years later, we performed a follow-up coronary angiogram, which revealed the CAF and the aneurysm were completely occluded and previous stent patency
Piao, Zhe Hao,Jin, Li,Kim, Ju Han,Ahn, Youngkeun,Kim, Young Jo,Cho, Myeong Chan,Kim, Chong Jin,Kim, Hyo Soo,Liu, Bin,Jeong, Myung Ho Elsevier 2017 The American journal of cardiology Vol.120 No.2
<P>Previous trials have found that statin therapy reduces low-density lipoprotein cholesterol (LDL-C) level and the risk of cardiovascular events. However, the benefit of statin therapy in patients with baseline LDL-C levels ≤ 50 mg/dl is less clear. Therefore, the aim of this study was to assess whether patients with acute myocardial infarction (AMI) who have baseline LDL-C levels ≤ 50 mg/dl would benefit from statin therapy in real-world clinical practice. We analyzed the clinical data of 1,048 patients (67.3 ± 12.6 years, 69.6% men) with AMI, who had baseline LDL-C levels ≤ 50 mg/dl from the Korean Acute Myocardial Infarction Registry data between November 2005 and May 2014. They were divided into 2 groups based on whether they were prescribed statins or not at discharge (statin and nonstatin group, n = 738 and 310, respectively). The primary end point was the major adverse cardiac event (MACE), defined as the composite of all-cause mortality, recurrent myocardial infarction, and repeated percutaneous coronary intervention or coronary artery bypass grafting. MACE occurred in 9.2% of the statin group versus 19.6% in the nonstatin group during the 12-month follow-up. Statin therapy significantly reduced the risk of MACE (hazard ratio [HR] 0.60, 95% CI 0.39 to 0.94, p = 0.025) and coronary artery bypass grafting (HR 0.27, 95% CI 0.08 to 0.96, p = 0.043). There was a trend of reduced cardiac death in the statin group compared with the nonstatin group (HR 0.52, 95% CI 0.26 to 1.02, p = 0.059). Statin therapy for patients with AMI with LDL-C levels ≤ 50 mg/dl was associated with improved outcomes. Therefore, statin therapy is feasible and effective, even in AMI patients with extremely low levels of LDL-C.</P>
( Zhe Hao Piao ),( Myung Ho Jeong ),( Young Keun Ahn ),( Young Jo Kim ),( Myeong Chan Cho ),( Chong Jin Kim ),( Hyo Soo Kim ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Coronary spasm is associated with endothelial dysfunction and statins have been shown to improve endothelial function. However, the benefit of statin therapy in patients with coronary spasm-induced acute myocardial infarction (AMI) is remains unclear. The purpose of this study was to determine whether statin therapy beneficial in patients with coronary spasm-induced AMI. Methods: We analyzed 501 patients with coronary spasm-induced AMI and survived at discharge from the Korean AMI Registry between November 2005 and May 2013. They were divided into 2 groups according to the prescribing of statins at discharge (statin group n = 292; nonstatin group n = 209). The primary endpoint was the composite of 1-year major adverse cardiac events, including death, recurrent MI, target vessel revascularization. Results: During a median follow-up of 346 days, the primary end points occurred in 17 patients. Statin therapy significantly reduced the risk of the composite primary endpoint (adjusted hazard ratio [HR]: 0.30; 95% confidence interval [CI]: 0.09 to 0.97; p = 0.045). Statin therapy reduced the risk of myocardial infarction (HR: 0.19; 95% CI: 0.04 to 0.93; p = 0.040). However, there was no difference in the risk of the composite of all-cause death. Conclusions: Statin therapy in patients with coronary spasm-induced AMI was associated with improved clinical outcome.